Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial

Application of HS221GI in treatment of influenza and ARVI in adults: a new approach – managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial

Aim. Evaluation of the efficacy and safety of the drug Aterixen® (XC221GI, 1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazine-2,6-dione), in the treatment of uncomplicated forms of influenza and other ARVI in adults. Materials and methods. The phase III clinical trial enrolled 260 people aged 18–6...

Full description

Bibliographic Details
Main Authors: Andrey G. Malyavin, Madina I. Bagaeva, Oleg V. Kalyuzhin
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2023-12-01
Series:Терапевтический архив
Subjects:
arvi
acute respiratory infections
influenza
respiratory viruses
aterixen®
хс221gi
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/626343/142220

Similar Items

Similar Items